720662-57-7

Usage

Uses

Used in Pharmaceutical Synthesis:
(2S)-1-(ethylamino)propan-2-ol serves as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be incorporated into the development of new drugs, contributing to advancements in medicinal chemistry.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In asymmetric synthesis reactions, (2S)-1-(ethylamino)propan-2-ol acts as a chiral auxiliary. This role is crucial for inducing and controlling the stereochemistry of the products, leading to the formation of enantiomerically pure compounds, which is essential in the production of single-enantiomer drugs.
Used as a Ligand in Metal-Catalyzed Asymmetric Reactions:
(2S)-1-(ethylamino)propan-2-ol also has the potential to be utilized as a ligand in metal-catalyzed asymmetric reactions. This application can enhance the efficiency and selectivity of these reactions, further expanding its utility in the synthesis of complex organic molecules and pharmaceuticals.
Used in Organic Chemical Research:
(2S)-1-(ethylamino)propan-2-ol's properties make it a valuable tool in organic chemical research. It can be employed to study reaction mechanisms, explore new synthetic methodologies, and develop innovative applications in the realm of organic chemistry.

Upstream product

• 75-04-7 ethylamine 
• 16088-62-3 (S)-Propylene oxide 
• 2799-17-9 (S)-1-amino-2-propanol 
• 75-07-0 acetaldehyde 

Relevant academic research and scientific papers

MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pha

2-(2-Oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents

From a fungicidal screen, we identified 2-(2-oxo-morpholin-3-yl)-acetamide derivatives as fungicidal agents against Candida species, additionally characterized by antifungal activity against Aspergillus species. However, development of this series was hampered by low plasmatic stability. Introduction of a gem-dimethyl on the 6-position of the morpholin-2-one core led to considerable improvement in plasmatic stability while maintaining in vitro antifungal activity. Further optimization of the series resulted in the discovery of N-(biphenyl-3-ylmethyl)-2-(4-ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)acetamide (87), which, in addition to fungicidal activity against Candida species, shows promising and broad antifungal in vitro activity against various fungi species, such as molds and dermatophytes. In vivo efficacy was also demonstrated in a murine model of systemic Candida albicans infection with a significant fungal load reduction in kidneys.

ANTIFUNGAL COMPOUNDS

The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprising them and to the compounds for use as a medicament, more in particular antifungal medicament.

ANTIFUNGAL COMPOUNDS

The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprising them and to the compounds for use as a medicament, more in particular antifungal medicament.